Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population
- 6 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 76 (6), 807-814
- https://doi.org/10.1007/s00228-020-02866-4
Abstract
Purpose Ethnicity plays a key role in deciding the direction of the association between serotonin transporter gene polymorphisms and treatment response of selective serotonin reuptake inhibitors (SSRIs). The present study explored the association of 5HTTLPR and 5HTTLPR-rs25531 polymorphisms with the treatment response of escitalopram in South Indian patients with major depressive disorder. Methods A total of 148 depressive patients receiving escitalopram 10–20 mg/day were genotyped for 5HTTLPR and rs25531 polymorphisms. Clinical assessment was done at baseline and after 4, 8, and 12 weeks using the 17-item Hamilton Depression Rating Scale (HDRS-17), Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression Scale (CGI). At the end of week 12, patients were defined as responders and non-responders based on HDRS17 and MADRS scores. Chi-square test and logistic regression analysis were performed to investigate the genotypic influence on treatment response. Comparison of continuous variables among different groups was done using Student’s t test or one-way ANOVA. Results Out of 148 study subjects, 65 (43.9%) were responders and 83 (56.08%) were non-responders. We observed a significant (p value < 0.001) association between LL genotype, LALA haplotypes, and 2 LA functional group with better treatment response to escitalopram. The decline in HDRS17 and MADRS score from baseline was significantly higher (p value < 0.001) in LL genotypes and homozygous LA carriers compared with other groups. Conclusion Results suggest that 5HTTLPR and rs-25531 polymorphisms can influence escitalopram treatment response in depressive patients in a South Indian population, LL genotypes and LALA haplotypes being the predictors of better treatment response.Keywords
This publication has 44 references indexed in Scilit:
- Pharmacogenetics in psychiatry: translating research into clinical practiceMolecular Psychiatry, 2011
- Pharmacogenetics of antidepressant responseJournal of Psychiatry and Neuroscience, 2011
- Pharmacogenetics and Psychoactive Drug Therapy: Ready for the Patient?Therapeutic Drug Monitoring, 2010
- Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disordersPsychiatry Research, 2007
- Genomics and the future of pharmacotherapy in psychiatryInternational Review of Psychiatry, 2007
- Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive DisorderAmerican Journal of Human Genetics, 2006
- Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531Molecular Psychiatry, 2006
- Escitalopram versus citalopram: the surprising role of the R-enantiomerPsychopharmacology, 2004
- Clinically Relevant Pharmacology of Selective Serotonin Reuptake InhibitorsClinical Pharmacokinetics, 1997
- Allelic Variation of Human Serotonin Transporter Gene ExpressionJournal of Neurochemistry, 1996